2 options
Medicare prescription drug legislation: An analysis of economic effect.
Connect to full text Available online
View online- Format:
- Book
- Thesis/Dissertation
- Author/Creator:
- Feng, Yan.
- Language:
- English
- Subjects (All):
- Health services administration.
- Economics.
- 0501.
- 0769.
- Penn dissertations--Health care management and economics.
- Health care management and economics--Penn dissertations.
- Penn dissertations--Managerial science and applied economics.
- Managerial science and applied economics--Penn dissertations.
- Local Subjects:
- Penn dissertations--Health care management and economics.
- Health care management and economics--Penn dissertations.
- Penn dissertations--Managerial science and applied economics.
- Managerial science and applied economics--Penn dissertations.
- 0501.
- 0769.
- Physical Description:
- 119 pages
- Contained In:
- Dissertation Abstracts International 70-10A.
- System Details:
- Mode of access: World Wide Web.
- text file
- Summary:
- Medicare had tried to incorporate outpatient prescription drugs into their benefits regime for many years. Medicare Prescription Drug, Improvement, and Modernization Act of 2003 is the most recent success after the repealed Medicare Catastrophic Coverage Act of 1988. There have been a lot of discussion and concerns about the effect of the prescription drug legislation about whether it creates big windfall profits for the private sectors. This thesis uses event study to investigate the economic effect of the Medicare legislations of 1988 and 2003 on two types of industries---pharmaceutical and health insurance. The event study uses daily stock return data from CRSP and analyzes the abnormal returns associated with important information about the prescription drug benefits. The empirical results suggest no evidence that the prescription drug legislation of covering outpatient drugs has led to expectations of windfall profits from the pharmaceutical and health insurance companies that significantly boost their stock prices. As far as abnormal returns are concerned, the cross-sectional analysis indicates that larger firms and better leveraged firms withstood the impact of prescription drug legislation better than their smaller and heavily debt financed peers. The empirical results also suggest that whether the prescription drug benefits are administered privately or publicly can influence the relevant industries differently.
- Notes:
- Thesis (Ph.D. in Health Care Management and Economics) -- University of Pennsylvania, 2009.
- Source: Dissertation Abstracts International, Volume: 70-10, Section: A, page: 3952.
- Adviser: Mark V. Pauly.
- Local Notes:
- School code: 0175.
- ISBN:
- 9781109428698
- Access Restriction:
- Restricted for use by site license.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.